CY1121267T1 - Τροποποιημενες σερπινες για τη θεραπευτικη αγωγη αιμορραγικων διαταραχων - Google Patents
Τροποποιημενες σερπινες για τη θεραπευτικη αγωγη αιμορραγικων διαταραχωνInfo
- Publication number
- CY1121267T1 CY1121267T1 CY20181101396T CY181101396T CY1121267T1 CY 1121267 T1 CY1121267 T1 CY 1121267T1 CY 20181101396 T CY20181101396 T CY 20181101396T CY 181101396 T CY181101396 T CY 181101396T CY 1121267 T1 CY1121267 T1 CY 1121267T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- modified
- hemorrhagic disorders
- modified serpins
- serpins
- Prior art date
Links
- 102000008847 Serpin Human genes 0.000 title abstract 3
- 108050000761 Serpin Proteins 0.000 title abstract 3
- 239000003001 serine protease inhibitor Substances 0.000 title abstract 3
- 208000031169 hemorrhagic disease Diseases 0.000 title 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 208000012287 Prolapse Diseases 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 208000034158 bleeding Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322091.8A GB201322091D0 (en) | 2013-12-13 | 2013-12-13 | Modified serpins for the treatment of bleeding disorders |
| PCT/EP2014/077783 WO2015086854A1 (en) | 2013-12-13 | 2014-12-15 | Modified serpins for the treatment of bleeding disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121267T1 true CY1121267T1 (el) | 2020-05-29 |
Family
ID=50030900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101396T CY1121267T1 (el) | 2013-12-13 | 2018-12-27 | Τροποποιημενες σερπινες για τη θεραπευτικη αγωγη αιμορραγικων διαταραχων |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9982035B2 (enExample) |
| EP (2) | EP3434689A1 (enExample) |
| JP (2) | JP6431541B2 (enExample) |
| KR (2) | KR101954945B1 (enExample) |
| CN (2) | CN110330563B (enExample) |
| AU (2) | AU2014363359B2 (enExample) |
| CA (1) | CA2933508C (enExample) |
| CY (1) | CY1121267T1 (enExample) |
| DK (1) | DK3080157T3 (enExample) |
| EA (1) | EA034050B1 (enExample) |
| ES (1) | ES2704058T3 (enExample) |
| GB (1) | GB201322091D0 (enExample) |
| HR (1) | HRP20182138T1 (enExample) |
| HU (1) | HUE042763T2 (enExample) |
| IL (2) | IL246180B (enExample) |
| LT (1) | LT3080157T (enExample) |
| MX (1) | MX357941B (enExample) |
| NZ (1) | NZ721918A (enExample) |
| PL (1) | PL3080157T3 (enExample) |
| PT (1) | PT3080157T (enExample) |
| RS (1) | RS58191B1 (enExample) |
| SI (1) | SI3080157T1 (enExample) |
| SM (1) | SMT201900016T1 (enExample) |
| TR (1) | TR201819781T4 (enExample) |
| WO (1) | WO2015086854A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| WO2018154044A1 (en) * | 2017-02-23 | 2018-08-30 | Umc Utrecht Holding B.V. | Modified serpins for the treatment of bradykinin-mediated disease |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| RU2663464C1 (ru) * | 2018-02-26 | 2018-08-06 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Комбинаторная терапия для лечения геморрагического шока |
| CA3117961A1 (en) * | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| CN110051830A (zh) * | 2019-03-14 | 2019-07-26 | 苏州新凝生物医药科技有限公司 | 一种protease nexin II\KPI蛋白突变体的应用 |
| EP4326869A4 (en) * | 2021-04-20 | 2025-12-10 | Univ Of Louisville | RECOMBINATING MICRO-NECK |
| US20250066436A1 (en) | 2021-12-22 | 2025-02-27 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium |
| EP4707391A1 (en) * | 2024-09-10 | 2026-03-11 | e-therapeutics PLC | Nucleic acid compounds for zpi inhibition |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| FR2599752B1 (fr) | 1986-06-10 | 1989-11-03 | Transgene Sa | Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine |
| DE3705745A1 (de) | 1987-02-23 | 1988-09-01 | Behringwerke Ag | Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci |
| US5612194A (en) | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
| IE902276A1 (en) | 1989-06-26 | 1991-01-16 | Akzo Nv | Serpin variants |
| US6566493B1 (en) | 1996-11-19 | 2003-05-20 | The University Of Vermont | Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties |
| WO2001055390A1 (en) | 2000-01-28 | 2001-08-02 | Human Genome Sciences, Inc. | Human serpin polynucleotides, polypeptides, and antibodies |
| JP2002010783A (ja) | 2000-06-29 | 2002-01-15 | Jcr Pharmaceuticals Co Ltd | 改変型ヒトプロテインｃインヒビター |
| US6924267B2 (en) | 2001-09-18 | 2005-08-02 | Suomen Punainen Risti Veripalvelu | Methods and active substances for protecting organs |
| JP2003093063A (ja) | 2001-09-20 | 2003-04-02 | Jcr Pharmaceuticals Co Ltd | 改変型ヒトプロテインｃインヒビター |
| WO2003039585A1 (en) | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors |
| FR2836143B1 (fr) | 2002-02-21 | 2004-04-16 | Servier Lab | Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2504365T3 (es) | 2002-12-05 | 2014-10-08 | Zz Biotech L.L.C. | La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante |
| WO2004056309A2 (en) | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| WO2006090282A2 (en) * | 2005-02-28 | 2006-08-31 | Universite De Lausanne | Recombinant inhibitor proteins of an hk14 protease and use thereof |
| US8106002B2 (en) | 2005-04-18 | 2012-01-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-cancer agent comprising protein C inhibitor |
| US8333076B2 (en) * | 2005-12-15 | 2012-12-18 | Gulfstream Aerospace Corporation | Isentropic compression inlet for supersonic aircraft |
| SG175602A1 (en) * | 2006-07-05 | 2011-11-28 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| WO2008059043A2 (en) | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Combination of coagulation factor viii with apc-resistant factor v |
| EP2081589B1 (en) | 2006-11-16 | 2010-10-06 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
| WO2008059009A2 (en) | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
| JP2010533684A (ja) | 2007-07-20 | 2010-10-28 | ユニベルシテ パリ サッド １１ | 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用 |
| GB0714649D0 (en) | 2007-07-27 | 2007-09-05 | Univ Leuven Kath | Novel viral replication inhibitors |
| WO2009055669A2 (en) | 2007-10-26 | 2009-04-30 | Oklahoma Medical Research Foundation | Monoclonal antibodies against activated and unactivated protein c |
| EP2055783A1 (en) * | 2007-10-30 | 2009-05-06 | VIB vzw | Insect inhibiting plant serpin mutants |
| CN101965409A (zh) | 2007-11-01 | 2011-02-02 | 罗切斯特大学 | 具有增加的稳定性的重组因子viii |
| CN101977626A (zh) * | 2008-01-21 | 2011-02-16 | 德莫迪斯公司 | 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 |
| WO2010081878A1 (en) | 2009-01-16 | 2010-07-22 | Universite Paris-Sud Xi | Mutated antithrombins, a process for preparing the same and their use as drugs |
| JP5727459B2 (ja) * | 2009-04-22 | 2015-06-03 | アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ | 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体 |
| US8557961B2 (en) * | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| EP2996713B1 (en) | 2013-05-15 | 2019-10-02 | Mor Research Applications Ltd. | Compositions and methods for treating post-operative complications of cardiopulmonary surgery |
| GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| WO2018154044A1 (en) * | 2017-02-23 | 2018-08-30 | Umc Utrecht Holding B.V. | Modified serpins for the treatment of bradykinin-mediated disease |
-
2013
- 2013-12-13 GB GBGB1322091.8A patent/GB201322091D0/en not_active Ceased
-
2014
- 2014-12-15 EA EA201691235A patent/EA034050B1/ru unknown
- 2014-12-15 CN CN201910704484.0A patent/CN110330563B/zh active Active
- 2014-12-15 MX MX2016007711A patent/MX357941B/es active IP Right Grant
- 2014-12-15 EP EP18190334.5A patent/EP3434689A1/en not_active Withdrawn
- 2014-12-15 CN CN201480075522.6A patent/CN105992771B/zh active Active
- 2014-12-15 ES ES14827185T patent/ES2704058T3/es active Active
- 2014-12-15 WO PCT/EP2014/077783 patent/WO2015086854A1/en not_active Ceased
- 2014-12-15 SM SM20190016T patent/SMT201900016T1/it unknown
- 2014-12-15 PT PT14827185T patent/PT3080157T/pt unknown
- 2014-12-15 PL PL14827185T patent/PL3080157T3/pl unknown
- 2014-12-15 NZ NZ721918A patent/NZ721918A/en unknown
- 2014-12-15 DK DK14827185.1T patent/DK3080157T3/en active
- 2014-12-15 KR KR1020167018756A patent/KR101954945B1/ko active Active
- 2014-12-15 RS RS20181470A patent/RS58191B1/sr unknown
- 2014-12-15 SI SI201430967T patent/SI3080157T1/sl unknown
- 2014-12-15 US US15/103,420 patent/US9982035B2/en active Active
- 2014-12-15 HU HUE14827185A patent/HUE042763T2/hu unknown
- 2014-12-15 HR HRP20182138TT patent/HRP20182138T1/hr unknown
- 2014-12-15 JP JP2016538525A patent/JP6431541B2/ja active Active
- 2014-12-15 CA CA2933508A patent/CA2933508C/en active Active
- 2014-12-15 AU AU2014363359A patent/AU2014363359B2/en active Active
- 2014-12-15 TR TR2018/19781T patent/TR201819781T4/tr unknown
- 2014-12-15 LT LTEP14827185.1T patent/LT3080157T/lt unknown
- 2014-12-15 KR KR1020197006015A patent/KR102186924B1/ko active Active
- 2014-12-15 EP EP14827185.1A patent/EP3080157B1/en active Active
-
2016
- 2016-06-13 IL IL246180A patent/IL246180B/en active IP Right Grant
-
2018
- 2018-05-04 US US15/971,692 patent/US10351619B2/en active Active
- 2018-10-31 JP JP2018204779A patent/JP6723319B2/ja not_active Expired - Fee Related
- 2018-11-08 IL IL262879A patent/IL262879A/en unknown
- 2018-12-17 AU AU2018279054A patent/AU2018279054A1/en not_active Abandoned
- 2018-12-27 CY CY20181101396T patent/CY1121267T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121267T1 (el) | Τροποποιημενες σερπινες για τη θεραπευτικη αγωγη αιμορραγικων διαταραχων | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1126072T1 (el) | Περιοχες gla ως θεραπευτικοι παραγοντες | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1121076T1 (el) | Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες | |
| CY1118744T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
| CY1121736T1 (el) | Άλατα aramchol | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| CY1121515T1 (el) | Μεθοδοι και συνθεσεις για την επουλωση πληγων | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| MX2016010360A (es) | Moleculas de anticuerpo para el virus del dengue y uso de las mismas. | |
| EA201101521A1 (ru) | Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| EA201590504A1 (ru) | Индолкарбоксамидные производные и их применение | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
| EA201491644A1 (ru) | Фармацевтические композиции |